ArticleInternational journal of clinical and experimental pathology2014
Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Genome wide association study of a Circadian Imbalance Index in 312,935 European ancestry UK Biobank participants identifies loci related to diabetes, mood and myocardial infarction.Research square · 2025Article
- Advanced diffusion-weighted imaging biomarkers for non-invasive assessment of tumor microenvironment in rectal cancer: restricted spectrum imaging.Abdominal radiology (New York) · 2025Article
- Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report.Journal of cancer research and clinical oncology · 2025Article
- Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity.Cell communication and signaling : CCS · 2024Review
- The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management.International journal of molecular sciences · 2022Review
- Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality.Scientific reports · 2021Article
- Differential expression of EphA5 protein in gastric carcinoma and its clinical significance.Oncology letters · 2019Article
- Article
- EphB3 Stimulates Cell Migration and Metastasis in a Kinase-dependent Manner through Vav2-Rho GTPase Axis in Papillary Thyroid Cancer.The Journal of biological chemistry · 2017Article
- Prognostic values of EphB1/B2 and p-EphB1/B2 expression in non-small cell lung cancer.International journal of clinical and experimental pathology · 2017Article
- Paradoxes of the EphB1 receptor in malignant brain tumors.Cancer cell international · 2017Review
- EphA8 is a prognostic marker for epithelial ovarian cancer.Oncotarget · 2016Article
- Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.Pathology oncology research : POR · 2016Article
- EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.Molecular cancer research : MCR · 2015Article
- Decreased expression of receptor tyrosine kinase of EphB1 protein in renal cell carcinomas.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant expression of receptors tyrosine kinase of Eph gene in human cancers is extensively documented. We previously found that EphB1 subtype is down-regulated in gastric cancer and colorectal cancer. Fore the more, decreased expression of EphB1 is related to invasion and metastasis in cancers. There is no published data regarding the role of EphB1 in ovarian cancer, which is the focus of the present study. The expression of EphB1 protein was determined in tissues from 74 patients with serous ovarian carcinoma and 12 normal ovarian epithelial tissues. The expression level of EphB1 protein in serous ovarian carcinoma was analyzed with respect to clinicopathological parameters and survival. EphB1 protein was positively stained in 12 normal ovarian epithelial samples, and negatively stained in 32 out of 74 (43.2%) serous ovarian cancers. Loss of expression of EphB1 protein was associated with higher tumor grade (P=0.006), metastasis (P=0.049) and high proliferative index Ki67 expression (P=0.022), but not with FIGO stage (P=0.0937), age at diagnosis (P=0.624), and diameter of carcinoma (P=0.108). In addition, loss of EphB1 protein in serous ovarian carcinoma was associated with a significantly worse overall survival (P=0.015). Our data indicate that loss of EphB1 protein is associated with metastasis and poorer survival in patients with serous ovarian cancer. EphB1 may be used as a prognostic marker and a therapeutic target in serous ovarian carcinoma.
Indexed as
Identifiers
24427352PMC3885486W189118017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.